Stay updated with breaking news from Yates Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the appointment of Ian T. Clark to its Board of Directors. Mr. Clark most recently served as Chief Executive Offi...
Search jobs 12-Jul-2021 Affinivax and Astellas Present Safety and Immunogenicity Data from Phase 2 Study of ASP3772, a Novel 24 valent MAPS™ Vaccine for Streptococcus pneumoniae Study results were selected for oral presentation at the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) ASP3772 has also received FDA Breakthrough Therapy Designation CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Affinivax, Inc. ("Affinivax") and Astellas Pharma Inc. (“Astellas”) announced results from the Phase 2 clinical trial of ASP3772...
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal modelComplete protection from COVID-19 disease by a single dose skin patch delivery using Vaxxas’ HD-MAP was demonstrated in a lethal challenge of the SARS-...
Press release content from Business Wire. The AP news staff was not involved in its creation. Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer April 20, 2021 GMT Affinivax Chief Business Officer Stuart Chaffee PhD (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 20, 2021-- Affinivax, Inc. (“Affinivax”), a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS™ (Multiple Antigen Presenting System) platform, today announced that Stuart Chaffee, PhD, has joined the company as Chief Business Officer. Dr. C...
KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks KVD900 Generally Safe and Well-Tolerated - Conference Call to Discuss Trial Results Today at 8:30 a.m. ET - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive topline data from a Phase 2 clinical trial de...